Merck built a wall of patents that keeps a cancer drug's price – and its profits – high. Hospitals often add to the cost for ...

What is the Cancer Calculus investigation? The Cancer Calculus is a yearlong investigation by the International Consortium of ...

New Trump tariffs on pharmaceuticals could double the cost of common prescription drugs, raising prices for medications like ...

Keytruda, manufactured by the US-based Merck & Co, is an immunotherapy drug that has become one of the world’s best-selling ...

“Building on the legacy of KEYTRUDA, we are committed to driving innovation in cancer care with new routes of administration and indications in difficult-to-treat and earlier stages of cancer,” said ...

A game changer in cancer treatment, Keytruda, works by harnessing the body’s immune system to attack cancer cells. While its ...

This marks the approval of the first and only subcutaneous immune checkpoint inhibitor in Europe that can be administered by a health care provider in as little as one minute “We are honored to ...

Keytruda was first approved by the US Food and Drug Administration (FDA) in 2014 for metastatic skin cancer and is now used ...

Merck & Co.'s Keytruda in the U.S. starts at $12,000 for a 200 mg dose. Costs go up from there based on the insurer, provider ...

The approval also covers Keytruda SC, known in the US as Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph).

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute RAHWAY, N.J.--(BUSINESS WIRE)-- Merck ...

Positive opinion granted for SC administration of KEYTRUDA for all adult indications approved in the European Union for KEYTRUDA Positive opinion also granted for KEYTRUDA as part of a perioperative ...